Recursion Pharmaceuticals (RXRX) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $1.68B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Najat Khan |
| IPO Date | 2021-04-16 | CAGR | 87.64% |
| Employees | 600 | Website | www.recursion.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $1.46B | P/E | -3.08 | Forward P/E | -3.58 | PEG | — |
| P/S | 80.51 | P/B | 4.9 | P/CF | -10.34 | P/FCF | -10.19 |
| Sales | $54.85M | Sales 1Y | -14.88% | Sales 3Y | 9.98% | Sales 5Y | 552.03% |
| EPS | $-1.04 | EPS 1Y | -41.57% | EPS 3Y | -22.96% | EPS 5Y | 42.12% |
| Sales QoQ | 18.51% | EPS QoQ | 13.64% | Sales QoQ Avg | 112.63% | EPS QoQ Avg | -8.87% |
| Gross Margin | -46.66% | Operating Margin | -991.72% | Profit Margin | -945.92% | ROCE | -49.78% |
| ROA | -43% | ROE | -50% | Altman Z Score | -0.28 | Piotroski Score | 3 |
| Current Ratio | 5.03 | Quick Ratio | 5.03 | Cash Ratio | 4.55 | Op. CF Ratio | -1.56 |
| Debt/Equity | 0.07 | Debt/Assets | 0.05 | Lt Debt/Equity | 0.04 | Lt Debt/Cap. | — |
| Intrst Cov. | -459.86 | Inventory Turnover | — | Asset Turnover | 0.05 | Receivables Turnover | 3.81 |
| Enterprise Value | $1.46B | P/E Ratio | -3.08 |
| Forward P/E | -3.58 | PEG Ratio | — |
| P/S Ratio | 80.51 | P/B Ratio | 4.9 |
| P/CF Ratio | -10.34 | P/FCF Ratio | -10.19 |
| EPS | $-1.04 | EPS Growth 1Y | -41.57% |
| EPS Growth 3Y | -22.96% | EPS Growth 5Y | 42.12% |
| Revenue Growth 1Y | -14.88% | Gross Margin | -0.47% |
| Operating Margin | -9.92% | Profit Margin | -9.46% |
| ROE | -0.5% | ROA | -0.43% |
| ROCE | -0.5% | Current Ratio | 5.03 |
| Quick Ratio | 5.03 | Cash Ratio | 4.55 |
| Debt/Equity | 0.07 | Interest Coverage | -459.86 |
| Altman Z Score | -0.28 | Piotroski Score | 3 |
Recursion Pharmaceuticals (RXRX) valuation & financials
Recursion Pharmaceuticals (RXRX) has a market capitalization of $1.68B and trades at a price-to-earnings ratio of -3.1. It operates in the Healthcare sector (Biotechnology).
Recursion Pharmaceuticals's revenue grew -14.9% over the last year.
Recursion Pharmaceuticals's next earnings report is scheduled for November 4, 2026 before market open; analysts estimate EPS of $-0.24. Check the earnings calendar to see all companies reporting this week.
Recursion Pharmaceuticals (RXRX) — frequently asked questions
When does Recursion Pharmaceuticals (RXRX) report earnings next?
Recursion Pharmaceuticals is expected to report earnings on November 4, 2026 before market open. Analysts estimate EPS of $-0.24.
What is Recursion Pharmaceuticals's market cap?
Recursion Pharmaceuticals (RXRX) has a market capitalization of $1.68B.
What is RXRX's P/E ratio?
Recursion Pharmaceuticals trades at a price-to-earnings ratio of -3.1, with trailing twelve-month EPS of $-1.04.
How fast is Recursion Pharmaceuticals growing?
Recursion Pharmaceuticals's revenue grew -14.9% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)